Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation

References

• Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-92; PMID:19558376; http://dx.doi.org/10.1111/j.1399-3062.2009.00411.x
   PubMed Web of Science ®Google Scholar
• Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberqhe P, Fischer A, Morschhauser F, Salles G, Feremans W et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107:3053-7; PMID:16254143; http://dx.doi.org/10.1182/blood-2005-01-0377
   PubMed Web of Science ®Google Scholar
• Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104:1661-7; PMID:16149091; http://dx.doi.org/10.1002/cncr.21391
   PubMed Web of Science ®Google Scholar
• Choquet S, Oertel S, LeBlond V, Riess H, Varoqueaux N, Dörken B, Trappe R. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86:599-607; PMID:17522862; http://dx.doi.org/10.1007/s00277-007-0298-2
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005; 5:566-72; PMID:15707412; http://dx.doi.org/10.1111/j.1600-6143.2004.00693.x
   PubMed Web of Science ®Google Scholar
• Fang ZP, Yu XF, Liu QF. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. NatI Med J China 2006; 86:2975-7
   Google Scholar
• Heslop HE, Slobod KS, Pule MA, hale GA, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925-35; PMID:19880495; http://dx.doi.org/10.1182/blood-2009-08-239186
   PubMed Web of Science ®Google Scholar
• Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-92; PMID:19558376; http://dx.doi.org/10.1111/j.1399-3062.2009.00411.x
   PubMed Web of Science ®Google Scholar
• Doubrovina E, Oflaz-Sozmen B, Prockop SE, kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119:2644-56; PMID:22138512; http://dx.doi.org/10.1182/blood-2011-08-371971
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185-91; PMID:8093146; http://dx.doi.org/10.1056/NEJM199404283301703
   PubMed Web of Science ®Google Scholar
• Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, Ljungman P, Engelhard D. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43:757-70; PMID:19043458; http://dx.doi.org/10.1038/bmt.2008.386
   PubMed Web of Science ®Google Scholar
• Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, Könecke C, Wolschke C, Bacher U, Zander AR et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol 2012; 159:172-81; PMID:22909192; http://dx.doi.org/10.1111/bjh.12013
   PubMed Web of Science ®Google Scholar
• Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jjovanovic B et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28:1038-46; PMID:20085936; http://dx.doi.org/10.1200/JCO.2009.25.4961
   PubMed Web of Science ®Google Scholar
• Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY, Tien HF, Chang HH, Lu MY, Lin TT et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 2009; 43:315-21; PMID:18836488; http://dx.doi.org/10.1038/bmt.2008.325
   PubMed Web of Science ®Google Scholar
• Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehée A, Rohrlich P, Peuchmaur M, Matthieu- Boué A, Fischer A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115:112-8; PMID:11722420; http://dx.doi.org/10.1046/j.1365-2141.2001.03041.x
   PubMed Web of Science ®Google Scholar
• Maximiano AC, Sanchez RA, Cantos SDIB, Mendez GM, Ronco IS, Provencio PM. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. Clin Transl Oncol 2010; 12:701-3; PMID:20947485; http://dx.doi.org/10.1007/s12094-010-0580-y
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Kawada H, Iwaki Y, Machida S, Tsuchiya T, Fukuda R, Hotta T. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma]. Rinsho Ketsueki 2004; 45:1255-7; PMID:15678918
   PubMedGoogle Scholar
• Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2012; 58:459-61; PMID:21584931; http://dx.doi.org/10.1002/pbc.23134
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97:1165-71; PMID:11222357; http://dx.doi.org/10.1182/blood.V97.5.1165
   PubMed Web of Science ®Google Scholar
• Rai KR. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol 2015; 8:85; PMID:26170206; http://dx.doi.org/10.1186/s13045-015-0165-x
   PubMed Web of Science ®Google Scholar
• Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol 2014; 3:4; PMID:24472371; http://dx.doi.org/10.1186/2162-3619-3-4
   PubMedGoogle Scholar
• Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol 2015; 8:104; PMID:26337639; http://dx.doi.org/10.1186/s13045-015-0195-4
   PubMed Web of Science ®Google Scholar
• Clavert A, Chevallier P, Guillaume T, Delaunay J, Le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P et al. Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transplant 2013; 48:734-6; PMID:23085828; http://dx.doi.org/10.1038/bmt.2012.203
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Castagna L, El-Cheikh J, Helvig A, Furst S, Faucher C, Vazquez A, Granata A, Coso D, Bouabdallah R et al. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol 2011; 39:892-6; PMID:21703987; http://dx.doi.org/10.1016/j.exphem.2011.06.006
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Kasamon YL, Bolanos-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA et al. Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-vs.-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2013; 19:1514-7; PMID:23871780; http://dx.doi.org/10.1016/j.bbmt.2013.07.013
   PubMed Web of Science ®Google Scholar
• Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13:196-206; PMID:22173060; http://dx.doi.org/10.1016/S1470-2045(11)70300-X
   PubMed Web of Science ®Google Scholar
• Gupta S, Fricker FJ, Gonzalez-Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 2010; 14:896-902; PMID:20642490; http://dx.doi.org/10.1111/j.1399-3046.2010.01370.x
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2:551-5; PMID:8616714; http://dx.doi.org/10.1038/nm0596-551
   PubMed Web of Science ®Google Scholar
• Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2008; 21:579-96; PMID:18790456; http://dx.doi.org/10.1016/j.beha.2008.06.003
   PubMed Web of Science ®Google Scholar
• D'Aveni M, Aissi-Rothe L, Venard V, Salmon A, Falenga A, Decot V, virion JM, Wang Y, Clement L, Latger-Cannard V et al. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2011; 24:224-32; PMID:21440066; http://dx.doi.org/10.1016/j.trim.2011.03.002
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang Y, Luo G, Li Y. The roles of stem cell memory T cells in hematological malignancies. J Hematol Oncol 2015; 8:113; PMID:26462561; http://dx.doi.org/10.1186/s13045-015-0214-5
   PubMed Web of Science ®Google Scholar
• Ricciardelli I, Blundell MP, Brewin J, Thrasher A, Pule M, Amrolia PJ. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 2014; 124:2514-22; PMID:25185261; http://dx.doi.org/10.1182/blood-2014-01-553362
   PubMed Web of Science ®Google Scholar
• Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90:453-63; PMID:9207483
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Xu LP, Chen H, Han W, Liu KY, Lu DP. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006; 20:365-8; PMID:16331281; http://dx.doi.org/10.1038/sj.leu.2403995
   PubMed Web of Science ®Google Scholar
• Vendramin A, Gimondi S, Bermema A, longoni P, Rizzitano S, Corradini P, Carniti C. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Biol Blood Marrow Transplant 2014; 20:2049-55; PMID:25246295; http://dx.doi.org/10.1016/j.bbmt.2014.09.011
   PubMed Web of Science ®Google Scholar
• Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, Zhang Y, Huang F, Zhou H, Fan Z et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol 2013; 6:15; PMID:23394705; http://dx.doi.org/10.1186/1756-8722-6-15
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen J, Que W. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients. Biol Blood Marrow Transplant 2012; 18:1164-73; PMID:22289799; http://dx.doi.org/10.1016/j.bbmt.2012.01.015
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119:3256-62; PMID:22337715; http://dx.doi.org/10.1182/blood-2011-09-380386
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013; 19:562-8; PMID:23266740; http://dx.doi.org/10.1016/j.bbmt.2012.12.013
   PubMed Web of Science ®Google Scholar
• Lu Y, Waller EK. Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant 2009; 15:1347-53; PMID:19822293; http://dx.doi.org/10.1016/j.bbmt.2009.07.015
   PubMed Web of Science ®Google Scholar
• Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 2010; 25:2089-98; PMID:20576725; http://dx.doi.org/10.1093/ndt/gfq231
   PubMed Web of Science ®Google Scholar
• Shapiro NL, Tang CG, Bhattacharyya N. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients. Laryngoscope 2011; 121:1718-25; PMID:21792960; http://dx.doi.org/10.1002/lary.21871
   PubMed Web of Science ®Google Scholar
• Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000; 96:1857-64; PMID:10961887
   PubMed Web of Science ®Google Scholar
• Liu Q, Xuan L, Liu H, Huang F, Zhou H, Fan Z, Zhao K, Wu M, Xu L, Zhai X et al. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 2013; 88:550-5; PMID:23564232; http://dx.doi.org/10.1002/ajh.23452
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86; PMID:17242396; http://dx.doi.org/10.1200/JCO.2006.09.2403
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, klingemann HG, Beatty P, Hows J, Thomas ED. Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15:825-8; PMID:7581076
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57:267-76; PMID:7004534
   PubMed Web of Science ®Google Scholar